Phase 3 tests showing Dupixent dramatically decreased itching and hives when compared to a placebo led to approval.
Healthcare & Pharmaceuticals
In a Phase 3 trial, orforglipron, the first small molecule GLP-1, successfully reduced A1C by an average of 1.3% to 1.6% across dosages.
Lecanemab is the only approved Aβ monoclonal antibody that binds and clears hazardous protofibrils.
All nine subjects of phase 1 injected without any serious adverse events.
Data from the danuglipron clinical development program will be presented at a scientific meeting or published in a peer-reviewed journal in the future.
Tolebrutinib was generally well tolerated by all subjects across all study arms.
IMDELLTRA’s safety profile was consistent with the recognized profile. Detailed DeLLphi-304 results will be presented at an upcoming medical congress.
The FDA’s animal testing requirement will be decreased, modified, or potentially replaced utilizing a variety of methodologies.
A one-size-fits-all strategy to protein purification is no longer practicable, given the development and transformation of the mAb market, notably the recent rapid emergence of biosimilars. To solve this, Cytiva created two new protein A resins, the MabSelect SuRe 70 and the MabSelect PrismA X. The different stages of drug […]
Novo Nordisk presented the full results of STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial that looked at the effects of once-weekly injectable Ozempic®.
